Valneva begins U.K. approval process for COVID-19 vaccine

By The Science Advisory Board staff writers

August 23, 2021 -- French firm Valneva has begun the regulatory submission process to the U.K.'s Medicines and Healthcare products Regulatory Agency for its COVID-19 vaccine candidate, VLA2001.

The candidate is a whole-virus, inactivated, adjuvanted vaccine -- the only one of its kind in clinical trials in Europe, according to the company. The company is conducting a phase III trial for the vaccine and hopes to receive approval for it before the end of the year.

In September 2020, Valneva entered into an agreement with the U.K. government for the option to purchase up to 190 million doses of the vaccine through 2025, it said.

Valneva begins phase III COVID-19 vaccine trial
Valneva announced it has initiated a phase III trial to evaluate its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. The company's Cov-Compare...
Valneva posts positive early clinical data for adjuvanted COVID-19 vaccine
Valneva is directing attention to positive results from the phase I/II clinical trial of its VLA2001, an inactivated, adjuvanted COVID-19 vaccine candidate.
Valneva begins COVID-19 vaccine production
Valneva has begun production of its inactivated COVID-19 vaccine candidate in conjunction with ongoing clinical studies from which the company expects...
Valneva begins clinical trials for inactivated, adjuvanted COVID-19 vaccine
Valneva has begun a phase I/II clinical trial to study its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
Dynavax partners on Valneva's SARS-CoV-2 vaccine candidate
Dynavax will supply its CpG 1018 adjuvant for use in Valneva's SARS-CoV-2 vaccine candidate, VLA2001, as part of a commercial partnership.

Copyright © 2021

Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter